Aptevo Therapeutics Inc (NASDAQ: APVO) stock jumped 6.32% on Monday to $0.20 against a previous-day closing price of $0.19. With 0.31 million shares changed hands, the volume of the stock remained lighter than its average volume of 0.48 million shares. The 52-week range on APVO shows that it touched its highest point at $7.20 and its lowest point at $0.15 during that stretch. It currently has a 1-year price target of $7.38. Beta for the stock currently stands at 5.00.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of APVO was up-trending over the past week, with a rise of 12.98%, but this was down by -38.45% over a month. Three-month performance dropped to -48.73% while six-month performance fell -88.26%. The stock lost -93.48% in the past year, while it has lost -91.29% so far this year. A look at the trailing 12-month EPS for APVO yields -2.05 with Next year EPS estimates of -1.36. For the next quarter, that number is -0.41. This implies an EPS growth rate of -262.41% for this year and 38.65% for next year.
Float and Shares Shorts:
At present, 17.62 million APVO shares are outstanding with a float of 17.42 million shares on hand for trading. On Oct 30, 2023, short shares totaled 0.1 million, which was 0.91% higher than short shares on Sep 28, 2023. In addition to Mr. Marvin L. White as the firm’s President, CEO & Director, Mr. Jeffrey G. Lamothe CA serves as its Executive VP & COO.
Through their ownership of 12.23% of APVO’s outstanding shares, institutional investors have minority control over the company. Other institutions hold 61.90% of APVO, in contrast to 27.64% held by mutual funds. Shares owned by individuals account for 2.06%. As the largest shareholder in APVO with 11.58% of the stake, Sabby Management LLC holds 1,334,169 shares worth 1,334,169. A second-largest stockholder of APVO, Armistice Capital LLC, holds 1,235,000 shares, controlling over 10.72% of the firm’s shares. The Vanguard Group, Inc. is the third largest shareholder in APVO, holding 221,064 shares or 1.92% stake. With a 0.80% stake in APVO, the Vanguard Extended Market Index Fu is the largest stakeholder. A total of 91,725 shares are owned by the mutual fund manager. The Fidelity Extended Market Index Fu, which owns about 0.49% of APVO stock, is the second-largest Mutual Fund holder. It holds 56,229 shares valued at 15800.0. T Rowe Price Total Equity Market holds 0.40% of the stake in APVO, owning 46,200 shares worth 12982.0.
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for APVO since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential. With APVO analysts setting a high price target of $10.00 and a low target of $4.75, the average target price over the next 12 months is $7.38. Based on these targets, APVO could surge 4900.0% to reach the target high and rise by 2275.0% to reach the target low. Reaching the average price target will result in a growth of 3590.0% from current levels.
Summary of Insider Activity:
Insiders traded APVO stock several times over the past three months with 0 Buys and 0 Sells. In these transactions, 0 shares were bought while 0 shares were sold. The number of buy transactions has increased to 21 while that of sell transactions has remained unmoved to 0 over the past year. The total number of shares bought during that period was 76,428 while 0 shares were sold.